News & AnalysisMOMA Therapeutics rakes in $150m Series BMOMA Therapeutics, a biopharmaceutical company, has closed $150 million in Series B financing.ByIris Dorbian10 May 2022•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs